TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32078929

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for dissociative seizures
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standardized Medical Care (SMC)
Number of subjects: 12
Study: 34949135

Group type: EXPERIMENTAL
Intervention: repetitive transorbital alternating current stimulation (rtACS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 16
Study: 33685421

Group type: EXPERIMENTAL
Intervention: S-1 monotherapy (80 mg/m2 orally administrated twice daily, at day 1–14, 16 cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin with vinorelbine combination therapy (cisplatin 80 mg/m2 at day 1, vinorelbine 25 mg/m2 at day 1, 8, 4 cycles)
Number of subjects: 0
Study: 32991728

Group type: EXPERIMENTAL
Intervention: Teams (inter-brain synchrony)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Inter-brain synchrony
Number of subjects: 174

Group type: COMPARATOR
Intervention: Self-reported group identification
Number of subjects: 174
Study: 32014692

Group type: EXPERIMENTAL
Intervention: Full ACT website (12 sessions)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Open components of ACT
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Engaged components of ACT
Number of subjects: 181

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Full ACT website
Number of subjects: 181
Study: 35382963

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg/h)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Ketamine (0.5 mg/kg/h)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dexmedetomidine (0.5 mcg/kg/h)
Number of subjects: 73
Study: 33509838

Group type: COMPARATOR
Intervention: SMS reminders (two SMS reminders sent 3 days and 1 day before the scheduled MCV1 date)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: SMS reminders coupled with a KES 150 incentive (sent 3 days before the scheduled MCV1 date)
Number of subjects: 537

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 537
Study: 32544499

Group type: EXPERIMENTAL
Intervention: Root canals prepared with ProTaper Next X3 rotary instrument (Dentsply Sirona) in experimental groups 1 (2 independent canals) and 3 (3 independent canals)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonprepared roots with 2 independent canals in group 2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonprepared roots with 3 independent canals in group 4
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of prepared roots with 2 canals (group 1) and nonprepared roots with 3 canals (group 4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prepared roots with MM canal (group 3)
Number of subjects: 40
Study: 34985236

Group type: EXPERIMENTAL
Intervention: End-range Maitland mobilization (MG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham manual therapy technique (CG)
Number of subjects: 40
Study: 34006049

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Paravertebral Block (PVB) with GA
Number of subjects: 130
Study: 32819981

Group type: EXPERIMENTAL
Intervention: Text-messaging smartphone application with messages chosen by a reinforcement learning algorithm
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Text-messaging smartphone application with uniform random messages from messaging banks
Number of subjects: 276

Group type: COMPARATOR
Intervention: Weekly mood message (control group)
Number of subjects: 276
Study: 34490850

Group type: EXPERIMENTAL
Intervention: ISC 17536 (28-day administration)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (28-day administration)
Number of subjects: 138
Study: 32727149

Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naftopidil analogues
Number of subjects: 0
Study: 35668304

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus chemotherapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 141
Study: 34185279

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 45
Study: 35138182

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Mindful Eating intervention
Number of subjects: 284
Study: 34415194

Group type: EXPERIMENTAL
Intervention: Mild dysplasia (Dejour type A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Severe dysplasia (Dejour type B)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal geometries
Number of subjects: 9
Study: 32798834

Group type: EXPERIMENTAL
Intervention: ACT Group (four-session, group-based ACT plus asthma education)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control Group (group-based asthma education talk plus three telephone follow-ups)
Number of subjects: 168
Study: 33079463

Group type: EXPERIMENTAL
Intervention: 50 g glycidyl ester-rich palm fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12 g 2/3-MCPD ester-rich hazelnut oil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control exposure (background exposure)
Number of subjects: 12
Study: 32465772

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 1020
Study: 36158840

Group type: EXPERIMENTAL
Intervention: Alprostadil (40 μg, three times per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (5 mg, three times per day)
Number of subjects: 102
Study: 32971524

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg, 3 times a day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 32947299

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with 1:2 polidocanol to air ratio
Number of subjects: 30

Group type: COMPARATOR
Intervention: Foam sclerotherapy with 1:4 polidocanol to air ratio
Number of subjects: 30
Study: 34506937

Group type: EXPERIMENTAL
Intervention: Capsules containing 300 mg of standardized extract from B. forficata leaves (2% total flavonoid content)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 92
Study: 33307353

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Control
Number of subjects: 984
Study: 33160882

Group type: EXPERIMENTAL
Intervention: Fasting high-intensity interval exercise (AME)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Postprandial high-intensity interval exercise (PME)
Number of subjects: 12
Study: 32186030

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with usual care (AP + UC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with usual care (EA + UC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study: 35976497

Group type: EXPERIMENTAL
Intervention: In-office 6% HP paint-on varnish
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: At-home 6% HP with adaptable tray
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: At-home 16% carbamide peroxide with custom tray
Number of subjects: 3

Group type: COMPARATOR
Intervention: All techniques (combined)
Number of subjects: 3
Study: 33045271

Group type: EXPERIMENTAL
Intervention: 70% ethanol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2.5% sodium hypochlorite
Number of subjects: 80

Group type: COMPARATOR
Intervention: 17% EDTA‐T
Number of subjects: 80
Study: 32333404

Group type: EXPERIMENTAL
Intervention: Multiple myeloma patients
Number of subjects: 283

Group type: COMPARATOR
Intervention: Non-Hodgkin's lymphoma patients
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Plerixafor added to mobilization
Number of subjects: 283
Study: 35420397

Group type: EXPERIMENTAL
Intervention: SARAsp‐Mix (biosimilar insulin aspart premix SAR341402 Mix 70/30)
Number of subjects: 402

Group type: COMPARATOR
Intervention: NN‐Mix (originator insulin aspart mix 70/30 - NovoMix® 30)
Number of subjects: 402

Group type: COMPARATOR
Intervention: SARAsp‐Mix vs NN‐Mix
Number of subjects: 402

Group type: COMPARATOR
Intervention: SARAsp‐Mix and NN‐Mix
Number of subjects: 402
Study: 34175862

Group type: EXPERIMENTAL
Intervention: Abrocitinib (200 mg)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Abrocitinib (100 mg)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study: 36401921

Group type: EXPERIMENTAL
Intervention: Parenteral vitamin C (100 mg/kg/d for 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 40
Study: 36175097

Group type: EXPERIMENTAL
Intervention: Point-of-care nucleic acid amplification testing (POC-NAAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scaled-up provider-initiated testing and counselling (SU-PITC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider-initiated testing and counselling (PITC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of POC-NAAT to PITC
Number of subjects: 0
Study: 34672148

Group type: EXPERIMENTAL
Intervention: Moderate work rate increasing rate (30 W/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relatively low work rate increasing rate (10 W/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Relatively high work rate increasing rate (60 W/min)
Number of subjects: 12
Study: 34284321

Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive strategy (30% of patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 34493575

Group type: EXPERIMENTAL
Intervention: Infarct progression rate (mL/h)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Good outcome (modified Rankin Scale score 0-2)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Collateral status
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Alberta Stroke Program Early CT Score (ASPECTS)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Blood glucose
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale (NIHSS) score
Number of subjects: 409
Study: 32910084

Group type: EXPERIMENTAL
Intervention: Internal limiting membrane peeling (Group A)
Number of subjects: 258

Group type: COMPARATOR
Intervention: No internal limiting membrane peeling (Group B)
Number of subjects: 258
Study: 35883016

Group type: EXPERIMENTAL
Intervention: Cranberry extract for symptoms of acute, uncomplicated UTI
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Script to explain the delayed antibiotic trial group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electronic diary for symptom rating
Number of subjects: 26
Study: 34222630

Group type: EXPERIMENTAL
Intervention: Small-caliber colonoscope
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 220
Study: 33066338

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Bifidobacterium breve PB04 and Lactobacillus rhamnosus KL53A
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 150
Study: 36243576

Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: tranexamic acid 0.5 g
Number of subjects: 175

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 175
Study: 32281816

Group type: EXPERIMENTAL
Intervention: Family DSME (Diabetes Self-Management Education)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard DSME
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Family DSME
Number of subjects: 142
Study: 34936528

Group type: EXPERIMENTAL
Intervention: TranS‐C
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: TranS‐C with text messages
Number of subjects: 176

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: TranS‐C and text messages
Number of subjects: 176
Study: 32660667

Group type: EXPERIMENTAL
Intervention: Oral quinine and intragastric placebo (OQGP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral placebo and intragastric quinine (OPGQ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral placebo and intragastric placebo (OPGP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral quinine and intragastric quinine (OQGQ)
Number of subjects: 32
Study: 35357449

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Taxane chemotherapy
Number of subjects: 741
Study: 32650126

Group type: EXPERIMENTAL
Intervention: Surviving Sepsis Campaign recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resuscitation recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management/adjuvant therapy recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial/source control recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition recommendations
Number of subjects: 0
Study: 34787653

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 34088230

Group type: EXPERIMENTAL
Intervention: Discrete-time decay model
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exchangeable, block-exchangeable, and discrete-time decay correlation structures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increasing period-length and cluster-period sizes
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increasing cluster-period size
Number of subjects: 44
Study: 32320043

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 514
Study: 36065582

Group type: EXPERIMENTAL
Intervention: Forensic Assertive Community Treatment (FACT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Outpatient psychiatric treatment including intensive case management
Number of subjects: 70
Study: 32951215

Group type: EXPERIMENTAL
Intervention: Home-based disability prevention program (up to six 1-hour home visits with an occupational therapist, up to four 1-hour home visits with a registered nurse, and up to $1,300 worth of home repairs, modifications, and assistive devices with a handyman over 4 months)
Number of subjects: 194
Study: 32470437

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenous once per week for 8 weeks, then twice per month for 8 doses, and once per month until disease progression.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenous once per week for 8 weeks, then twice per month for 16 weeks, and once per month until disease progression.
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg intravenous.
Number of subjects: 148
Study: 616874577

Group type: EXPERIMENTAL
Intervention: Non-caloric sweetened beverages (diet)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Water (water)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study: 36168741

Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study: 34468885

Group type: EXPERIMENTAL
Intervention: EDP-M (etoposide, doxorubicin, and cisplatin plus mitotane)
Number of subjects: 43
Study: 33629193

Group type: EXPERIMENTAL
Intervention: PVI + LAPWI using CB-A
Number of subjects: 120

Group type: COMPARATOR
Intervention: PVI + linear ablation using RFCA
Number of subjects: 120

Group type: COMPARATOR
Intervention: PVI alone using CB-A
Number of subjects: 120

Group type: COMPARATOR
Intervention: PVI alone using RFCA
Number of subjects: 120
Study: 34534030

Group type: EXPERIMENTAL
Intervention: Yoga program (12 sessions, once per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 33419518

Group type: EXPERIMENTAL
Intervention: Stress recovery intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional training (Control)
Number of subjects: 0
Study: 35951072

Group type: EXPERIMENTAL
Intervention: Fennel mixed with coarse salt for ironing, combined with umbilical moxibustion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 96
Study: 32629469

Group type: EXPERIMENTAL
Intervention: Manual segmentation using Horos software
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Semi-automatic segmentation using IPlan software
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Automated segmentation using BraTumIA software
Number of subjects: 58

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Semi-automated segmentation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Automated segmentation
Number of subjects: 58
Study: 35994774

Group type: COMPARATOR
Intervention: Saline placebo (N=46)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Midazolam placebo (N=105)
Number of subjects: 151
Study: 34328588

Group type: EXPERIMENTAL
Intervention: Educational book group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Non-educational book group
Number of subjects: 167

Group type: COMPARATOR
Intervention: No-book group
Number of subjects: 167
Study: 616173210

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation plus heart coherence training (HCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cardiac rehabilitation (no HCT group)
Number of subjects: 18
Study: 35257499

Group type: COMPARATOR
Intervention: HIIT-PLA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HIIT-CIT
Number of subjects: 81
Study: 33757499

Group type: EXPERIMENTAL
Intervention: HyFlex EDM glide path file
Number of subjects: 80

Group type: COMPARATOR
Intervention: PathFile
Number of subjects: 80
Study: 32342837

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 334
Study: 34380000

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 18
Study: 33180924

Group type: EXPERIMENTAL
Intervention: 1-drop mOPV2
Number of subjects: 378

Group type: COMPARATOR
Intervention: 2-drop mOPV2
Number of subjects: 378
Study: 33934981

Group type: EXPERIMENTAL
Intervention: POC management based on ROTEM results
Number of subjects: 67

Group type: COMPARATOR
Intervention: non POC management based on clinical experience
Number of subjects: 67
Study: 34097565

Group type: EXPERIMENTAL
Intervention: Assessment-oriented group action (AGA) with professional support
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (feedback only)
Number of subjects: 43
Study: 33352601

Group type: EXPERIMENTAL
Intervention: Rest redistribution set configuration
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Traditional set configuration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 36057581

Group type: EXPERIMENTAL
Intervention: EMG-based multi-Kalman filter approach
Number of subjects: 10
Study: 33428907

Group type: EXPERIMENTAL
Intervention: E4 15 mg/DRSP 3 mg (E4/DRSP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ethinylestradiol (EE) 30 µg/levonorgestrel (LNG)
Number of subjects: 98

Group type: COMPARATOR
Intervention: EE 20 µg/DRSP 3 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: EE 30 µg/LNG 150 µg
Number of subjects: 98
Study: 36223288

Group type: EXPERIMENTAL
Intervention: Ahmed FP7 Glaucoma Valve (AGV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Baerveldt 101-350 Glaucoma Implant (BGI)
Number of subjects: 43
Study: 33616655

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 45
Study: 33048964

Group type: EXPERIMENTAL
Intervention: Facemask use
Number of subjects: 7687

Group type: COMPARATOR
Intervention: No facemask
Number of subjects: 7687
Study: 35107354

Group type: EXPERIMENTAL
Intervention: sMCL augmentation repair
Number of subjects: 54

Group type: COMPARATOR
Intervention: sMCL reconstruction
Number of subjects: 54
Study: 34187228

Group type: EXPERIMENTAL
Intervention: Lidocaine as a sodium channel blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Del Nido Cardioplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard cardioplegic techniques
Number of subjects: 0
Study: 33197158

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 203

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 203
Study: 32647051

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 4 × 4‐min HIIT (85‐95% peak heart rate) performed thrice weekly for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 30
Study: 34610731

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MCE)
Number of subjects: 14
Study: 33755218

Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral rinse
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral rinse and oropharyngeal spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 100
Study: 35458151

Group type: EXPERIMENTAL
Intervention: Cycle Ergometry with Enteral Nutrition (Group 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cycle Ergometry with Protein-Enriched Enteral Nutrition (Group 3)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional Physiotherapy with Enteral Nutrition (Control, Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All groups (Group 1, Group 2, Group 3)
Number of subjects: 41
Study: 32376105

Group type: EXPERIMENTAL
Intervention: EAPP training courses (experimental group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Originally scheduled activities only (control group)
Number of subjects: 70